Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH

Single-agent vemurafenib leads to a rapid and sustained clinical response in severe multisystem LCH but does not eradicate the disease. Longitudinal assessment of BRAF V600E during treatment shows that clinical remission can occur despite significant amounts of mutated BRAF.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kolenová, Alexandra, Schwentner, Raphaela, Jug, Gunhild, Simonitsch-Klupp, Ingrid, Kornauth, Christoph, Plank, Lukáš, Horáková, Júlia, Bodová, Ivana, Sýkora, Tomáš, Geczová, Lucia, Holter, Wolfgang, Minkov, Milen, Hutter, Caroline
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Exceptional Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738993/
https://ncbi.nlm.nih.gov/pubmed/29296950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003533
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados